CAR T-Cell Therapy – Pipeline Insights – 2018

SKU: DPI4 | Last Updated On: Nov 06 2019 | No. of Pages: 185 | Available Formats

In May 2019, the FDA granted orphan drug designation to Poseida Therapeutics’ P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma.

CAR T-Cell Therapy

  • The “CAR T-Cell Therapy – Pipeline Insights 2018″ report covers an in-depth analysis of CAR T-Cell therapy drug molecules currently undergoing clinical studies. It provides a deep understanding of potential CAR T-cell therapy drug molecules across all drug development phases.
  • The report assesses the pipeline CAR T-cell therapy molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), by type of developer(s), target therapeutic areas and disease indications, key target antigens, source of T-cells (autologous and allogeneic) and route of administration (intravenous infusion and regional course), therapy type (monotherapy, combination products).
  • The report provides a snapshot of discontinued and dormant drugs too. Also, the report includes critical insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
  • The report covers company profiles key players in developing CAR T-cell therapy drug molecules. The company profile includes essential info on overview, financial highlights, product portfolio, business strategies, and key recent developments.

 

Why should I purchase this report?

• To obtain an understanding of the current CAR T-cell therapy pipeline landscape.

• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.

• To valuably optimize R&D activities in-line with robust therapeutic drug markets.

• To devise strategic initiatives by identifying prospective partners with progressing projects.

 

Market Outlook

  • Among the current initiatives going on to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell therapy (CAR-T) has emerged as a potent and useful therapeutic intervention that will eradicate tumor cells, with minimal side effects.
  • These will target cancer cells and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is a treatment type in which T-cells derived from patient’s blood are modified in the laboratory by adding the individual protein receptor called Chimeric Antigen Receptor (CAR) on the T-cells that will bind to the infected cancer cells and kill them thereby cures cancer.
  • It is based on the principle of utilizing the inherent potential of the immune system to target thereby destroy the diseased cells.
  • The key characteristics that promote CAR-T cells suitable for use as useful therapeutic tools include target specificity, adaptability, and their capability to retain immunologic memory.
  • This potential approach of using the body’s immune cells to target cancer cells has been successfully used in the treatment of Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Leukemia, Pancreatic Cancer, Breast Cancer, Neuroblastoma, Acute Myeloid Leukemia, Colorectal Cancer, Hepatocellular Carcinoma.
  • The most popular targets of CAR-T therapies have been developed against hematological cancers and solid tumors. CAR builds of clinical stage therapies based on the generation of CAR-T product (first generation, second generation, third generation and fourth generation), type of vector (lentivirus, retrovirus, mRNA electroporation, sleeping beauty), type of binding domain (murine, humanized, fully human and rabbit-derived), and other vectors) and kind of co-stimulatory domain used.

 

What’s trending in this market?

  • The efforts on potential product candidates have constructed the intellectual framework for the buildup of several start-ups.
  • The ongoing strategies have also led to the discovery of several novel molecular targets. The U.S. Food and Drug Administration has approved two CAR-T cell therapies of Mariah for children and adult lymphoblastic leukemia and Yescarta for advanced lymphoma in adults.
  • This is expected to add the growth of the market over the forecast period. The success in early phase trials assessed the necessity of evaluating the treatment modality in multiple centers and larger patients.
  • Currently, 99 CAR-T Cell-based therapies are in the clinical pipeline, and most of them are in Phase-I and Phase-I/II clinical trials.
  • The first commercial application is expected to be available from 2020 of CAR T Cell therapy for the treatment of Mantle Non-Hodgkin’s lymphoma. The KITE Pharma in collaboration with the National Cancer Institute developed anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) that is in the pre-registration phase.

 

Drivers & Restraints

  • The side effects of using this cell therapy may lead to cytokine release syndrome (CRS) and other neurological problems involving seizures, coma, hallucinations, and delirium is expected to hinder the market growth.
  • Increasing of cancer incidence in adults and children, and rising number of cancer patients showing less response to alternative treatments is expected to faster the growth of the global CAR-T cell therapy market and expected to have a high demand for a valid and reliable therapeutic approach for improvement of the quality of patient lives.
  • Further, increasing government initiatives for developing healthcare infrastructure and encouraging research for cell therapy in cancer is going to fuel the growth of the market
  • The advancement of CAR T Cell therapy in future will be driven mainly by academia and will need the support for the high early phase clinical trials that will promisingly cover the way for a new form of targeted, exportable immunotherapy for patients with cancer cells.
  • The manufacturing of CD19 CAR T cell therapy CTL019 is in a way that will modernize the process of using the treatment globally.
  • The anticipation of manufacturing and regulatory issues before they arise and actively addressing the concerns early helps to accelerate the process that will bring this promising therapeutic approach to more cancer patients in the future.

 

The scope of the Report

• Provides comprehensive understanding of active CAR T-cell therapy pipeline drug candidates

• Includes complete pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.

• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration

• Provides a comparative analysis of key marketed products and pipeline drug candidates

• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators

• Provides essential info on players involved in clinical R&D of CAR T-cell therapy drug candidates.

• Provides in-depth coverage of crucial news related to CAR T-cell therapy drug molecules, including significant mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.

 

Why should I purchase this report?

• To obtain an understanding of the current CAR T-cell therapy pipeline landscape.

• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.

• To valuably optimize R&D activities in-line with robust therapeutic drug markets.

• To devise strategic initiatives by identifying prospective partners with progressing projects.

CAR T-cell Therapies

01: Executive Summary

 

02: Scope of the Report

 

03: Introduction

3.1 CAR T-cell Therapies – Overview

3.2 CAR T-cell Therapies –Role in the treatment of various types of tumors

 

04: CAR T-cell Therapies – Pipeline Landscape

4.1 Overview of Pipeline CAR T-cell Therapies

4.2 CAR T-cell Therapies Filed and Phase III Products

4.3 Comparative Analysis

4.4 CAR T-cell Therapies Phase II Products

4.5 Comparative Analysis

4.6 CAR T-cell Therapies Phase I and IND Filed Products

4.7 Comparative Analysis

4.8 CAR T-cell Therapies Discovery and Pre-Clinical Stage Products

4.9 Comparative Analysis

4.10 CAR T-cell Therapies – Discontinued Products

4.11 CAR T-cell Therapies – Dormant Products

 

05: CAR T-cell Therapies by molecule type

5.1 Small molecule

5.2 Gene Therapies

5.3 Others

 

06: Comparative Analysis of Marketed and Pipeline CAR T-cell Therapies

 

07: Key Pipeline Product Profiles

 

08: Competitive Landscape

8.1 Prominent Vendors:

8.1a Celgene

8.2 Other Prominent Vendors:

8.2a Aeon Therapeutics

8.2b Autolus

8.2c Bellicum

8.2d Beijing Immunochina

8.2e Celyad

8.2f Eureka

8.2g Juno

8.2h Kite

8.2i Intrexon

8.2j Marino Biotechnology

8.2k Pinze Lifetechnology

8.2l Shanghai Unicar-Therapy

8.2m Sinobioway cell Therapy

8.2n Sirtex Medical

8.2o Ziopharm

 

09: Key News

9.1 Major Mergers and Acquisitions

9.2 Product News (including clinical trial progression updates)

 

 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!